Find verified Rly-2608 API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Rly-2608 for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Rly-2608 API.
Alternate Names: Zovegalisib, Pan-mutant PI3Ka Inhibitor RLY-2608
CAS No: 2733573-94-7
PubChem CID: 166822065
Mol Formula: C29H14ClF5N6O2
Mol Weight: 608.9 g/mol
IUPAC Name: N-[(3R)-3-(2-chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxo-2,3-dihydroisoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzami -Show More
API Description: RLY-2608 is an investigational allosteric pan-mutant PI3Kα inhibitor. It is being developed to treat cancers with PIK3CA mutations, such as breast and gynecologic cancers. Unlike earlier PI3K inhibitors, it aims for mutant selectivity, reducing toxicity. Currently under clinical trials, not yet FDA-approved.
